The increase in coronary flow induced by converting enzyme inhibitors is prostacyclin independent.
Tio
R A
RA
Department of Clinical Pharmacology, University of Gronigen, The Netherlands.
van Wijngaarden
J
J
Scholtens
E
E
van Gilst
W H
WH
de Langen
C D
CD
Wesseling
H
H
D015121:6-Ketoprostaglandin F1 alpha / Q000096:biosynthesis; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology; D002216:Captopril / Q000031:analogs & derivatives / Q000494:pharmacology; D003326:Coronary Circulation / Q000187:drug effects*; D015773:Enalaprilat / Q000494:pharmacology; D011464:Epoprostenol / Q000502:physiology*; D066298:In Vitro Techniques; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains
D000806:Angiotensin-Converting Enzyme Inhibitors; C044958:zofenopril; D015121:6-Ketoprostaglandin F1 alpha; D002216:Captopril; D011464:Epoprostenol; D015773:Enalaprilat; D001920:Bradykinin; D007213:Indomethacin